

b.) Remarks

Claim 1 has been amended to recite that the selective serotonin reuptake inhibitor is paroxetine or fluoxetine in conformity with the Examiner's statement that Applicants have evidenced a synergistic combination with paroxetine and fluoxetine. Additionally, claims 8, 54 and 57 are amended in conformity therewith and claims 55 and 58 are amended to correct typographical errors. No new matter has been added.

Entry hereof is earnestly solicited.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our below listed address.

Respectfully submitted,

/Lawrence S. Perry/
Lawrence S. Perry
Attorney for Applicants
Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO
1290 Avenue of the Americas
New York, New York 10104-3800
Facsimile: (212) 218-2200

LSP\ac